Sana fills 2 senior roles as the Seattle biotech shifts focus


Sana CEO Steve Harr says the company is transitioning from a research-based biotech to one focused on delivering innovative gene and cell-based medicines.

Previous New York real estate group to open Brazilian steakhouse restaurant at Wynwood Walk
Next Polis signs $38.5B budget for post-pandemic era